Geoffrey S. Ginsburg

Geoffrey S. Ginsburg

Auto-generated profile, based on publicly available information

Geoffrey S. Ginsburg

All of Us Research Program, National Institutes of Health

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Health Affairs
Verified
Journal Article
Closed access
GGGeoffrey S. Ginsburg
Geoffrey S. Ginsburg
Kathryn A. PhillipsKathryn A. Phillips
Kathryn A. Phillips
Precision medicine is making an impact on patients, health care delivery systems, and research participants in ways that were only imagined fifteen years ago when the human genome was first sequenc...

1 December 2009 in Translational Research
Verified
Journal Article
Closed access
GGGeoffrey S. Ginsburg
Geoffrey S. Ginsburg
HWHuntington F. Willard
Huntington F. Willard

1 October 2009 in JACC
Verified
Journal Article
Closed access
Deepak VooraDeepak Voora
Deepak Voora
SSSvati H. Shah
Svati H. Shah
ISIvan Spasojevic
Ivan Spasojevic
SAShazia Ali
Shazia Ali
CRCarol R. Reed
Carol R. Reed
GGGeoffrey S. Ginsburg
Geoffrey S. Ginsburg

1 September 2009 in Cell Host & Microbe
Verified
Journal Article
Closed access
AZAimee K. Zaas
Aimee K. Zaas
MCMinhua Chen
Minhua Chen
JVJay Varkey
Jay Varkey
TVTimothy Veldman
Timothy Veldman
AHAlfred O. Hero
Alfred O. Hero
GGGeoffrey S. Ginsburg
Geoffrey S. Ginsburg

22 September 2011 in Annual Review of Genomics and Human Genetics
Verified
Journal Article
Closed access
ICIsaac S. Chan
Isaac S. Chan
GGGeoffrey S. Ginsburg
Geoffrey S. Ginsburg
Personalized medicine is a broad and rapidly advancing field of health care that is informed by each person's unique clinical, genetic, genomic, and environmental information. Personalized medicine depends on multidisciplinary health care teams and integrated technologies (e.g., clinical decision support) to utilize our molecular understanding of disease in order to optimize preventive health care strategies. Human genome information now allows providers to create optimized care plans at every stage of a disease, shifting the focus from reactive to preventive health care. The further integration of personalized medicine into the clinical workflow requires overcoming several barriers in education, accessibility, regulation, and reimbursement. This review focuses on providing a comprehensive understanding of personalized medicine, from scientific discovery at the laboratory bench to integration of these novel ways of understanding human biology at the bedside.

20 January 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ETEphraim L. Tsalik
Ephraim L. Tsalik
RHRicardo Henao
Ricardo Henao
MNMarshall Nichols
Marshall Nichols
TBThomas Burke
Thomas Burke
EKEmily R. Ko
Emily R. Ko
CWChristopher Wildrick Woods
Christopher Wildrick Woods
Acute respiratory infections caused by bacterial or viral pathogens are among the most common reasons for seeking medical care. Despite improvements in pathogen-based diagnostics, most patients receive inappropriate antibiotics. Host response biomarkers offer an alternative diagnostic approach to direct antimicrobial use. This observational cohort study determined whether host gene expression patterns discriminate noninfectious from infectious illness and bacterial from viral causes of acute respiratory infection in the acute care setting. Peripheral whole blood gene expression from 273 subjects with community-onset acute respiratory infection (ARI) or noninfectious illness, as well as 44 healthy controls, was measured using microarrays. Sparse logistic regression was used to develop classifiers for bacterial ARI (71 probes), viral ARI (33 probes), or a noninfectious cause of illness (26 probes). Overall accuracy was 87% (238 of 273 concordant with clinical adjudication), which was more accurate than procalcitonin (78%, P < 0.03) and three published classifiers of bacterial versus viral infection (78 to 83%). The classifiers developed here externally validated in five publicly available data sets (AUC, 0.90 to 0.99). A sixth publicly available data set included 25 patients with co-identification of bacterial and viral pathogens. Applying the ARI classifiers defined four distinct groups: a host response to bacterial ARI, viral ARI, coinfection, and neither a bacterial nor a viral response. These findings create an opportunity to develop and use host gene expression classifiers as diagnostic platforms to combat inappropriate antibiotic use and emerging antibiotic resistance.